AllianceBernstein’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

AllianceBernstein’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-237,830	Closed	-$159K	–	3290
2024 Q1	$159K	Hold	237,830	–	–	﹤0.01%	2966
2023 Q4	$129K	Sell	237,830 -16,191	-6%	-$7.46K	﹤0.01%	3033
2023 Q3	$152K	Hold	254,021	–	–	﹤0.01%	3012
2023 Q2	$330K	Buy	254,021 +87,950	+53%	+$120K	﹤0.01%	2827
2023 Q1	$292K	Sell	166,071 -186,000	-53%	-$531K	﹤0.01%	2784
2022 Q4	$1.11M	Buy	352,071 +200,000	+132%	+$776K	﹤0.01%	2227
2022 Q3	$745K	Sell	152,071 -287,616	-65%	-$1.48M	﹤0.01%	2448
2022 Q2	$1.82M	Buy	439,687 +287,616	+189%	+$1.24M	﹤0.01%	2009
2022 Q1	$884K	Buy	152,071 +300	+0.2%	+$1.78K	﹤0.01%	2470
2021 Q4	$1.14M	Hold	151,771	–	–	﹤0.01%	2409
2021 Q3	$1.37M	Hold	151,771	–	–	﹤0.01%	2373
2021 Q2	$1.82M	Sell	151,771 -4,670	-3%	-$52.9K	﹤0.01%	2253
2021 Q1	$1.96M	Buy	156,441 +3,400	+2%	+$45.8K	﹤0.01%	2113
2020 Q4	$2.39M	Buy	153,041 +27,700	+22%	+$324K	﹤0.01%	1868
2020 Q3	$1.18M	Sell	125,341 -19,900	-14%	-$215K	﹤0.01%	2108
2020 Q2	$1.3M	Hold	145,241	–	–	﹤0.01%	2072
2020 Q1	$925K	Hold	145,241	–	–	﹤0.01%	2070
2019 Q4	$1.22M	Hold	145,241	–	–	﹤0.01%	2197
2019 Q3	$1.31M	Sell	145,241 -9,600	-6%	-$108K	﹤0.01%	2148
2019 Q2	$1.67M	Buy	154,841 +11,800	+8%	+$125K	﹤0.01%	2075
2019 Q1	$1.36M	Hold	143,041	–	–	﹤0.01%	2113
2018 Q4	$1.64M	Hold	143,041	–	–	﹤0.01%	1941
2018 Q3	$2.42M	Hold	143,041	–	–	﹤0.01%	1809
2018 Q2	$2.03M	Sell	143,041 -36,762	-20%	-$611K	﹤0.01%	1904
2018 Q1	$3.42M	Sell	179,803 -10,780	-6%	-$230K	﹤0.01%	1452
2017 Q4	$3.13M	Hold	190,583	–	–	﹤0.01%	1533
2017 Q3	$2.86M	Buy	190,583 +100,342	+111%	+$1.11M	﹤0.01%	1592
2017 Q2	$794K	Hold	90,241	–	–	﹤0.01%	2413
2017 Q1	$469K	Sell	90,241 -10,200	-10%	-$40.9K	﹤0.01%	2560
2016 Q4	$306K	Buy	100,441 +9,100	+10%	+$33.1K	﹤0.01%	2741
2016 Q3	$423K	Hold	91,341	–	–	﹤0.01%	2586
2016 Q2	$529K	Hold	91,341	–	–	﹤0.01%	2505
2016 Q1	$553K	Sell	91,341 -10,200	-10%	-$61.2K	﹤0.01%	2383
2015 Q4	$927K	Sell	101,541 -5,100	-5%	-$39.3K	﹤0.01%	2164
2015 Q3	$601K	Sell	106,641 -130	-0.1%	-$1.07K	﹤0.01%	2417
2015 Q2	$1.18M	Buy	106,771 +10,200	+11%	+$132K	﹤0.01%	2184
2015 Q1	$1.51M	Hold	96,571	–	–	﹤0.01%	1939
2014 Q4	$1.47M	Hold	96,571	–	–	﹤0.01%	1955
2014 Q3	$1.04M	Hold	96,571	–	–	﹤0.01%	2172
2014 Q2	$1.48M	Hold	96,571	–	–	﹤0.01%	2001
2014 Q1	$1.75M	Buy	96,571 +11,000	+13%	+$212K	﹤0.01%	1814
2013 Q4	$1.19M	Hold	85,571	–	–	﹤0.01%	2061
2013 Q3	$897K	Sell	85,571 -1,029	-1%	-$10.2K	﹤0.01%	2184
2013 Q2	$676K	Buy	+86,600	New	+$756K	﹤0.01%	2302

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AllianceBernstein's SGMO Position: Q2 2024 in Review

AllianceBernstein sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2024, closing a stake of 237,830 shares — an estimated $159K sold.

AllianceBernstein first reported a position in SGMO in Q2 2013 and held it in 44 quarters. The position peaked at $3.42M in Q1 2018. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

AllianceBernstein reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
AllianceBernstein sold 237,830 SANGAMO THERAPEUTICS INC shares in Q2 2024, an estimated $159K.
AllianceBernstein first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 44 quarters.
AllianceBernstein's SANGAMO THERAPEUTICS INC position peaked at $3.42M in Q1 2018.
129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.